In vivo study of famotidine tablet 40 mg
Not Applicable
- Conditions
- ---.
- Registration Number
- IRCT20230222057495N1
- Lead Sponsor
- Aria Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Age between 18 to 50 years
Non smoking
BMI below 30 kg/m2
Exclusion Criteria
Blood pressure below 90/60 or more than 140/90 mmHg
Smoking person (more than 10 /day)
Using any kinds of medicine, alcohol or opioids during 2 weeks before starting the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Famotidine plasma concentrations. Timepoint: 0, 20 ? 40 ? 60 ? 80 ? 100 ? 120 ? 150 ? 180 ? 240 ? 300 ? 360? 420? 600 ? 720 minutes after dose. Method of measurement: By HPLC- UV analytical instrument.
- Secondary Outcome Measures
Name Time Method . Timepoint: . Method of measurement: .;. Timepoint: . Method of measurement: .